|Slideshows|December 13, 2018

5 Classic Hallucinogens Studied in the Treatment of Addictions

This slideshow provides information about the compounds, clinically relevant attributes, approximate dose, and data under study.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Retention in Care: The Good, the Bad, and the Ugly

ByLiana Hamdan,Andres Avellaneda Ojeda, MD,Benjamin Li, MD

January 28th 2026

Innovative Sciences: Eric Nestler, MD, PhD Reflects on Research and Leadership in Medicine

ByEric J. Nestler, MD, PhD

January 21st 2026

Precision Medicine for Opioid Use Disorder: Insights From New Review

ByPoorvanshi Alag, MD,Jessica Walters

January 19th 2026

Do ADHD Stimulant Medications Have an Effect on Substance Use?

ByJessica Walters

January 18th 2026

A Network-Based Approach to Depression, Neuropathic Pain, and Substance Use Disorder Using Coadministered TMS and Ketamine

BySteven R. Devore Best, MD

January 15th 2026

Latest CME

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

5 Classic Hallucinogens Studied in the Treatment of Addictions

Newsletter

Related Content

Retention in Care: The Good, the Bad, and the Ugly

Innovative Sciences: Eric Nestler, MD, PhD Reflects on Research and Leadership in Medicine

Precision Medicine for Opioid Use Disorder: Insights From New Review

Do ADHD Stimulant Medications Have an Effect on Substance Use?

A Network-Based Approach to Depression, Neuropathic Pain, and Substance Use Disorder Using Coadministered TMS and Ketamine

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Trending on Psychiatric Times

Depression and Long COVID Outcomes in Women: New Data Analysis

Artificial Intelligence, Job Loss, and the Psychiatric Significance of Work

Patterns of Propensity: A Review of Heinrichs’ How Psychiatrists Make Decisions

Investigational Psilocybin for PTSD and Ongoing Trials

In Memoriam: Elise Snyder, MD, A Legacy of Mentoring to Psychotherapists in China